SCYNEXIS, Inc. has announced the resumption of patient dosing in the Phase 3 MARIO study of ibrexafungerp, an oral antifungal medication, following the lifting of a clinical hold by the FDA. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback